On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment (“Series C”). The shares of the Series C have a 7.5% annual dividend and are ...
Roche Holding AG Akt 1.04% CHF232.83B ...
“I’m not opposed to the concept of equity financing, I believe that preserving equity is fundamental to preserving a Founder’s vision,” said Ryan Saadi, Founder and CEO of Tevogen Bio. “From a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback